Provided by Tiger Trade Technology Pte. Ltd.

Assembly Biosciences

26.90
+0.68002.59%
Volume:69.86K
Turnover:1.88M
Market Cap:425.48M
PE:-5.85
High:27.48
Open:26.75
Low:26.00
Close:26.22
52wk High:39.71
52wk Low:7.75
Shares:15.82M
Float Shares:7.55M
Volume Ratio:0.70
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6000
EPS(LYR):-6.6911
ROE:-36.94%
ROA:-15.96%
PB:2.33
PE(LYR):-4.02

Loading ...

Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27%

Simply Wall St.
·
Jan 22

BUZZ-Assembly Biosciences rises as Gilead opts to license co's HSV therapies

Reuters
·
Dec 23, 2025

Assembly Biosciences Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 23, 2025

BRIEF-Gilead Sciences Exercises Option To License Assembly Biosciences’ Helicase-Primase Inhibitor Programs For Recurrent Genital Herpes

Reuters
·
Dec 22, 2025

Gilead - Assembly Bio to Receive $35 Mln for Gilead's Hsv Option

THOMSON REUTERS
·
Dec 22, 2025

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10, 2025

Assembly Biosciences Reports Interim Phase 1b Data Showing Reductions in HSV-2 Shedding and Lesion Rates

MT Newswires Live
·
Dec 09, 2025

Assembly Biosciences Reports Positive Interim Results From Phase 1B Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates Abi-1179 and Abi-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

THOMSON REUTERS
·
Dec 09, 2025

Assembly Biosciences Reports Positive Phase 1b Results for Long-Acting HSV Inhibitors ABI-1179 and ABI-5366

Reuters
·
Dec 09, 2025

Assembly Biosciences Inc : Mizuho Raises Target Price to $40 From $29

THOMSON REUTERS
·
Nov 20, 2025

Mizuho Securities Reaffirms Their Buy Rating on Assembly Biosciences (ASMB)

TIPRANKS
·
Nov 20, 2025

Assembly Biosciences: Strong Clinical Execution and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
Nov 14, 2025

Assembly Biosciences Q3 EPS $(0.72) Beats $(0.78) Estimate, Sales $10.789M Beat $7.459M Estimate

Benzinga
·
Nov 11, 2025

Assembly Biosciences reports Q3 EPS (72c), consensus (65c)

TIPRANKS
·
Nov 11, 2025

Assembly Biosciences Q3 net loss narrows, raises $175 mln

Reuters
·
Nov 11, 2025

Assembly Biosciences reports positive interim results for ABI-5366 in Phase 1b genital herpes study

Reuters
·
Nov 11, 2025

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

THOMSON REUTERS
·
Nov 11, 2025

Assembly Biosciences Q3 Basic EPS USD -0.72

THOMSON REUTERS
·
Nov 11, 2025

Assembly Biosciences announces Phase 1b data for ABI-4334

TIPRANKS
·
Nov 07, 2025

Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334

Reuters
·
Nov 07, 2025